Fritextsökning
Artiklar per år
Innehållstyper
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current focus is on her next field: the role of gut flora in human health.
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Tataa förstärker på marknadssidan
Tataa Biocenter har anställt Johanna Nilsson som marknadschef, Head of Marketing.
-
Barns läkemedelsanvändning i centrum för Årets farmaceut
Ett långt och träget arbete för bättre läkemedelsanvändning för barn gör att Per Nydert vid Astrid Lindgrens barnsjukhus utses till Årets farmaceut 2023.
-
Styrelseordförande på svenskt medtechbolag polisanmäls för olovlig avlyssning
Det fortsätter att storma på Prostalund. Efter att hela ledningsgruppen, inklusive vd, sagt upp sig har personer i styrelsen nu polisanmälts. UPPDATERAD
-
Prostalunds vd avgår – ”Ytterst beklagligt”
Vd:n för det skånska medtechbolaget Prostalund lämnar företaget. Det innebär att hela ledningen nu har sagt upp sig.
-
Flera avhopp från skånskt medtechbolag: ”Mycket olyckligt”
Tre av fyra personer i ledningsgruppen för Prostalund har valt att lämna sina tjänster.
-
Here are the pharmaceutical companies best prepared for AI
How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.
-
Study: Semaglutide tablet produces weight loss
The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.
-
Ny genterapi mot hemofili B godkänd i EU
CSL Behring presenterar nu den första genterapeutiska behandlingen mot blödarsjuka typ B, hemofili B. Vektorn är ett adeno-associerat virus.
-
Editorial: ”AI that both impresses and frightens”
”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writes in an editorial.
-
Hello Jenni Nordborg!
Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.
-
Han blir Lif:s nya vd
Det blir Johan Färnstrand, idag chef vid Aleris, som tar över vd-posten för branschorganisationen Lif efter avgående Anders Blanck.
-
“Everyone is screaming for talent”
Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Horizons in Biologics & Bioprocessing conference on 15 December.
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tablet was available that was soon to help millions of people worldwide and break all sales records.
-
“We are Europe’s hotspot in life science”
The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees the anniversary as a recognition of MVA’s explosive power.
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward
-
Karolinska nionde bästa sjukhuset i världen i ny rankning
Återigen rankar Newsweek de bästa sjukhusen i världen. I år har de listat de sjukhus som är bäst på att använda ny teknik. Karolinska universitetssjukhuset utmärker sig inom artificiell intelligens och hamnar på plats 9 av 300 sjukhus.
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.